Abstract:Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal disorder caused by the deficiency of arylsulfatase A (ASA), resulting in impaired degradation of sulfatide, an essential sphingolipid of myelin. The clinical manifestations of MLD are characterized by progressive demyelination and subsequent neurological symptoms resulting in severe debilitation. The availability of therapeutic options for treating MLD is limited but expanding with a number of early stage clinical trials already in progress. In the development of therapeutic approaches for MLD, scientists have been facing a number of challenges including blood-brain barrier (BBB) penetration, safety issues concerning therapies targeting the central nervous system, uncertainty regarding the ideal timing for intervention in the disease course, and the lack of more in-depth understanding of the molecular pathogenesis of MLD. Here, we discuss the current status of the different approaches to developing therapies for MLD. Hematopoietic stem cell transplantation has been used to treat MLD patients, utilizing both umbilical cord blood and bone marrow sources. Intrathecal enzyme replacement therapy and gene therapies, administered locally into the brain or by generating genetically modified hematopoietic stem cells, are emerging as novel strategies. In pre-clinical studies, different cell delivery systems including microencapsulated cells or selectively neural cells have shown encouraging results. Small molecules that are more likely to cross the BBB can be used as enzyme enhancers of diverse ASA mutants, either as pharmacological chaperones, or proteostasis regulators. Specific small molecules may also be used to reduce the biosynthesis of sulfatides, or target different affected downstream pathways secondary to the primary ASA deficiency. Given the progressive neurodegenerative aspects of MLD, also seen in other lysosomal diseases, current and future therapeutic strategies will be complementary, whether used in combination or separately at specific stages of the disease course, to produce better outcomes for patients afflicted with this devastating inherited disorder.

Importance of the glycosylation and polyadenylation variants in metachromatic leukodystrophy pseudodeficiency phenotype

Delay of myelin formation in arylsulphatase A-deficient mice

Developing therapeutic approaches for metachromatic leukodystrophy

A systematic review on the birth prevalence of metachromatic leukodystrophy

Identification of two novel arylsulfatase A mutations with a polymorphism as a cause of metachromatic leukodystrophy

Biochemical and molecular analysis of pediatric patients with metachromatic leukodystrophy in South China: functional characterization of five novel ARSA variants

Exploring the effect of disease causing mutations in metal binding sites of human ARSA in metachromatic leukodystrophy

A Novel Arsa Gene Mutation C.302delg In A Chinese Patient With Metachromatic Leukodystrophy

Motor and psycho-cognitive clinical types in adult metachromatic leukodystrophy: genotype/phenotype relationships?

[Differentiation between arylsulfatase A deficiency and pseudo-deficiency]

A novel homozygous PSAP mutation identified by whole exome sequencing in a consanguineous family with metachromatic leukodystrophy: a case report

[Metachromatic leukodystrophy (MLD) and Multiple sulphatase deficiency (MSD)]

Oligomerization capacity of two arylsulfatase A mutants: C300F and P425T

Molecular analysis of ARSA and PSAP genes in twenty-one Italian patients with metachromatic leukodystrophy: identification and functional characterization of 11 novel ARSA alleles

[Analysis of ARSA Mutations in a Chinese Family with Metachromatic Leukodystrophy].

Identification of Novel ARSA Mutations in Chinese Patients with Metachromatic Leukodystrophy.

Clinical Characteristics and Diagnosis of Metachromatic Leukodystrophy in 10 Cases

Complete Correction of Brain and Spinal Cord Pathology in Metachromatic Leukodystrophy Mice

[Analysis of ARSA gene variant in an infant with late infantile metachromatic leukodystrophy].

Analysis of a splice-site mutation in the sap-precursor gene of a patient with metachromatic leukodystrophy

Ex vivo cell-mediated gene therapy for metachromatic leukodystrophy using neurospheres